Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway
Introduction Empagliflozin is an established sodium-glucose cotransporter 2 inhibitor with reported anti-inflammatory activity, but its effects on advanced glycation end product/high-glucose-induced inflammatory injury in skeletal muscle cells remain unclear. Methods A GEO-derived transcriptomic dataset from gastrocnem...